Insulin-like growth factor 1 receptor targeted therapeutics: Novel compounds and novel treatment strategies for cancer medicine

Recent Patents on Anti-Cancer Drug Discovery

Volumn 4, Issue 1, 2009, Pages 54-72

  Hewish, Madeleine ^a   Chau, Ian ^a   Cunningham, David ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Antibody; Cancer; Growth hormone; IGF 1R; IGF 1R inhibitor; Insulin receptor; Insulin like growth factor; Insulin like growth factor inhibitor; Targeted therapy; Tyrosine kinase inhibitor

Indexed keywords

3 BROMO 5 TERT BUTYL 4 HYDROXYBENZYLIDENEMALONONITRILE; 4 AMINO 5 (3 BENZYLOXYPHENYL) 7 [3 (1 PYRROLIDINYLMETHYL)CYCLOBUTYL] 7H PYRROLO[2,3 D]PYRIMIDINE; AMG 479; ANTINEOPLASTIC AGENT; AVE 1642; BIIBO 22; BMS 536924; BMS 536942; BMS 554417; CARBOPLATIN; CP 751871; DEXAMETHASONE; DOCETAXEL; EM 164; ERLOTINIB; GROWTH HORMONE RECEPTOR ANTAGONIST; GROWTH HORMONE RELEASING HORMONE ANTAGONIST; H 7C10; IMC A12; INSM 18; MK 0646; NAVELBINE; NORDIHYDROGUAIARETIC ACID; NVP ADW 642; NVP AEW 541; OCTREOTIDE; PACLITAXEL; PEGVISOMANT; PICROPODOPHYLLIN; PROTEIN TYROSINE KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR ANTIBODY; SOMATOMEDIN RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; INSULIN RECEPTOR; PROTEIN KINASE INHIBITOR; SOMATOMEDIN C RECEPTOR;

ABDOMINAL PAIN; ADD ON THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; AUTOCRINE EFFECT; BREAST CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CLINICAL TRIAL; COLON CANCER; COLORECTAL CANCER; CONSTIPATION; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DOWNSTREAM PROCESSING; DRUG EFFICACY; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; DRUG POTENTIATION; DRUG STRUCTURE; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GLIOBLASTOMA; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; HYPERGLYCEMIA; HYPERURICEMIA; HYPOMAGNESEMIA; IC 50; INJECTION SITE REACTION; INSULIN RESISTANCE; KIDNEY CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MALIGNANT NEOPLASTIC DISEASE; MELANOMA; MESOTHELIOMA; MULTIPLE MYELOMA; NAUSEA; NEOPLASM; NEUROENDOCRINE TUMOR; NEUROPATHY; NEUTROPENIA; NONHUMAN; OVARY CANCER; PANCREAS CANCER; PARACRINE SIGNALING; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; PRURITUS; PSORIASIS; PURPURA; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER; STOMATITIS; STRUCTURE ANALYSIS; THROMBOCYTOPENIA; VOMITING; WEIGHT REDUCTION; ANIMAL; BREAST TUMOR; CHEMISTRY; COLORECTAL TUMOR; DRUG ANTAGONISM; FEMALE; LUNG TUMOR; MALE; PANCREAS TUMOR; PHYSIOLOGY; PROSTATE TUMOR;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COLORECTAL NEOPLASMS; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PROTEIN KINASE INHIBITORS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 62749203737     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489209787002515     Document Type: Review

References (149)

1. Furstenberger G, Senn HJ. Insulin-like growth factors and cancer. Lancet Oncol 2002; 3(5): 298-302.
2. Hankinson SE, Willett WC, Colditz GA, et al. Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998; 351(9113): 1393-1396.
3. Yu H, Spitz MR, Mistry J, et al. Plasma levels of insulin-like growth factor-I and lung cancer risk: A case-control analysis. J Natl Cancer Inst 1999; 91(2): 151-156.
4. Wu X, Zhao H, Do KA, et al. Serum levels of insulin growth factor (IGF-I) and IGF-binding protein predict risk of second primary tumors in patients with head and neck cancer. Clin Cancer Res 2004; 10(12 Pt 1): 3988-3995.
5. Ma J, Pollak MN, Giovannucci E, et al. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. J Natl Cancer Inst 1999; 91(7): 620-625.
6. Bergmann U, Funatomi H, Yokoyama M, Beger HG, Korc M. Insulin-like growth factor I overexpression in human pancreatic cancer: Evidence for autocrine and paracrine roles. Cancer Res 1995; 55(10): 2007-2011.
7. Xie Y, Skytting B, Nilsson G, Brodin B, Larsson O. Expression of insulin-like growth factor-1 receptor in synovial sarcoma: Association with an aggressive phenotype. Cancer Res 1999; 59(15): 3588-3591.
8. Chan JM, Stampfer MJ, Giovannucci E, et al. Plasma insulin-like growth factor-I and prostate cancer risk: A prospective study. Science 1998; 279(5350): 563-566.
9. Helle SI. The insulin-like growth factor system in advanced breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18(1): 67-79.
10. Papadimitrakopoulou VA, Brown EN, Liu DD, et al. The prognostic role of loss of insulin-like growth factor-binding protein-3 expression in head and neck carcinogenesis. Cancer Lett 2006; 239(1): 136-143.
11. Chang YS, Wang L, Suh YA, et al. Mechanisms underlying lack of insulin-like growth factor-binding protein-3 expression in non-small-cell lung cancer. Oncogene 2004; 23(39): 6569-6580.
12. Baglietto L, English DR, Hopper JL, et al. Circulating insulin-like growth factor-I and binding protein-3 and the risk of breast cancer. Cancer Epidemiol Biomarkers Prev 2007; 16(4): 763-768.
13. Renehan AG, Jones J, Potten CS, Shalet SM, O'Dwyer ST. Elevated serum insulin-like growth factor (IGF)-II and IGF binding protein-2 in patients with colorectal cancer. Br J Cancer 2000; 83(10): 1344-1350.
14. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev 2000; 21(3): 215-244.
15. Ouban A, Muraca P, Yeatman T, Coppola D. Expression and distribution of insulin-like growth factor-1 receptor in human carcinomas. Hum Pathol 2003; 34(8): 803-908.
16. Camirand A, Zakikhani M, Young F, Pollak M. Inhibition of insulin-like growth factor-1 receptor signaling enhances growth-inhibitory and proapoptotic effects of gefitinib (Iressa) in human breast cancer cells. Breast Cancer Res 2005; 7(4): 570-579.
17. Jones HE, Goddard L, Gee JM, et al. Insulin-like growth factor-I receptor signalling and acquired resistance to gefitinib (ZD1839; Iressa) in human breast and prostate cancer cells. Endocr Relat Cancer 2004; 11(4): 793-814.
18. Chakravarti A, Loeffler JS, Dyson NJ. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 2002; 62(1): 200-207.
19. Liu B, Fang M, Lu Y, Mendelsohn J, Fan Z. Fibroblast growth factor and insulin-like growth factor differentially modulate the apoptosis and G1 arrest induced by anti-epidermal growth factor receptor monoclonal antibody. Oncogene 2001; 20(15): 1913-1922.
20. Sakamoto M, Kondo A, Kawasaki K, et al. Analysis of gene expression profiles associated with cisplatin resistance in human ovarian cancer cell lines and tissues using cDNA microarray. Hum Cell 2001; 14(4): 305-315.
21. Shimizu C, Hasegawa T, Tani Y, et al. Expression of insulin-like growth factor 1 receptor in primary breast cancer: Immunohistochemical analysis. Hum Pathol 2004; 35(12): 1537-1542.
22. Abe S, Funato T, Takahashi S, et al. Increased expression of insulin-like growth factor I is associated with Ara-C resistance in leukemia. Tohoku J Exp Med 2006; 209(3): 217-228.
23. Miller BS, Yee D. Type I insulin-like growth factor receptor as a therapeutic target in cancer. Cancer Res 2005; 65(22): 10123-10127.
24. Cappuzzo F, Toschi L, Tallini G, et al. Insulin-like growth factor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 2006; 17(7): 1120-1127.
25. Cardillo MR, Monti S, Di Silverio F, et al. Insulin-like growth factor (IGF)-I, IGF-II and IGF type I receptor (IGFR-I) expression in prostatic cancer. Anticancer Res 2003; 23(5A): 3825-3835.
26. Chan JM, Stampfer MJ, Ma J, et al. Insulin-like growth factor-I (IGF-I) and IGF binding protein-3 as predictors of advanced-stage prostate cancer. J Natl Cancer Inst 2002; 94(14): 1099-1106.
27. Zhai GG, Malhotra R, Delaney M, et al. Radiation enhances the invasive potential of primary glioblastoma cells via activation of the Rho signaling pathway. J Neurooncol 2006; 76(3): 227-237.
28. Takahari DT, Yamada Y, Okita N, et al. Relationship of insulin-like growth factor-1 receptor and epidermal growth factor receptor expression to clinical outcomes in patients with colorectal cancer. ASCO Annual Meeting Proceedings Part 1. J Clin Oncol 2007; Vol. 25; 18S, (June 20 Suppl): Abstr 4117.
29. Lee CT, Wu S, Gabrilovich D, et al. Antitumor effects of an adenovirus expressing antisense insulin-like growth factor I receptor on human lung cancer cell lines. Cancer Res 1996; 56(13): 3038-3041.
30. Shapiro DN, Jones BG, Shapiro LH, Dias P, Houghton PJ. Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J Clin Invest 1994; 94(3): 1235-1242.
31. Reinmuth N, Liu W, Fan F, et al. Blockade of insulin-like growth factor I receptor function inhibits growth and angiogenesis of colon cancer. Clin Cancer Res 2002; 8(10): 3259-3269.
32. Yee D. Targeting insulin-like growth factor pathways. Br J Cancer 2006; 94(4): 465-468.
33. Tao Y, Pinzi V, Bourhis J, Deutsch E. Mechanisms of disease: Signaling of the insulin-like growth factor 1 receptor pathway--therapeutic perspectives in cancer. Nat Clin Pract Oncol 2007; 4(10): 591-602.
34. Stephen RL, Shaw LE, Larsen C, Corcoran D, Darbre PD. Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 2001; 276(43): 40080-40086.
35. Sachdev P, Jiang YX, Li W, et al. Differential requirement for Rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J Biol Chem 2001; 276(28): 26461-26471.
36. Sell C, Dumenil G, Deveaud C, et al. Effect of a null mutation of the insulin-like growth factor I receptor gene on growth and transformation of mouse embryo fibroblasts. Mol Cell Biol 1994; 14(6): 3604-3612.
37. O'Connor R, Kauffmann-Zeh A, Liu Y, et al. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol 1997; 17(1): 427-435.
38. Holzenberger M, Dupont J, Ducos B, et al. IGF-1 receptor regulates lifespan and resistance to oxidative stress in mice. Nature 2003; 421(6919): 182-187.
39. Baserga R, Peruzzi F, Reiss K. The IGF-1 receptor in cancer biology. Int J Cancer 2003; 107(6): 873-877.
40. Dunn SE, Hardman RA, Kari FW, Barrett JC. Insulin-like growth factor 1 (IGF-1) alters drug sensitivity of HBL100 human breast cancer cells by inhibition of apoptosis induced by diverse anticancer drugs. Cancer Res 1997; 57(13): 2687-2693.
41. Baserga R. The insulin-like growth factor I receptor: A key to tumor growth? Cancer Res 1995; 55(2): 249-252.
42. Belfiore A. The role of insulin receptor isoforms and hybrid insulin/ IGF-I receptors in human cancer. Curr Pharm Des 2007; 13(7): 671-686.
43. Frasca F, Pandini G, Scalia P, et al. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol 1999; 19(5): 3278-3288.
44. Stoll BA. Western nutrition and the insulin resistance syndrome: A link to breast cancer. Eur J Clin Nutr 1999; 53(2): 83-87.
45. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4(7): 505-518.
46. Baserga R. The insulin-like growth factor-I receptor as a target for cancer therapy. Expert Opin Ther Targets 2005; 9(4): 753-768.
47. Kuribayashi A, Kataoka K, Kurabayashi T, Miura M. Evidence that basal activity, but not transactivation, of the epidermal growth factor receptor tyrosine kinase is required for insulin-like growth factor I-induced activation of extracellular signal-regulated kinase in oral carcinoma cells. Endocrinology 2004; 145(11): 4976-4984.
48. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006; 441(7092): 424-430.
49. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: Comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5(10): 2503-2512.
50. Osborne CK, Bolan G, Monaco ME, Lippman ME. Hormone responsive human breast cancer in long-term tissue culture: Effect of insulin. Proc Natl Acad Sci USA 1976; 73(12): 4536-4540.
51. McKern NM, Lawrence MC, Streltsov VA, et al. Structure of the insulin receptor ectodomain reveals a folded-over conformation. Nature 2006; 443(7108): 218-221.
52. Lou M, Garrett TP, McKern NM, et al. The first three domains of the insulin receptor differ structurally from the insulin-like growth factor 1 receptor in the regions governing ligand specificity. Proc Natl Acad Sci USA 2006; 103(33): 12429-12434.
53. Zhang Q, Thomas SM, Lui VW, et al. Phosphorylation of TNF-alpha converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci USA 2006; 103(18): 6901-6906.
54. Morgillo F, Woo JK, Kim ES, Hong WK, Lee HY. Heterodimerization of insulin-like growth factor receptor/epidermal growth factor receptor and induction of survivin expression counteract the antitumor action of erlotinib. Cancer Res 2006; 66(20): 10100-10111.
55. Slomiany MG, Black LA, Kibbey MM, et al. Insulin-like growth factor-1 receptor and ligand targeting in head and neck squamous cell carcinoma. Cancer Lett 2007; 248(2): 269-279.
56. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M. Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Natl Cancer Inst 2001; 93(24): 1852-1857.
57. Slomiany MG, Black LA, Kibbey MM, Day TA, Rosenzweig SA. IGF-1 induced vascular endothelial growth factor secretion in head and neck squamous cell carcinoma. Biochem Biophys Res Commun 2006; 342(3): 851-858.
58. Carlberg M, Larsson O. Stimulatory effect of PDGF on HMG-CoA reductase activity and N-linked glycosylation contributes to increased expression of IGF-1 receptors in human fibroblasts. Exp Cell Res 1996; 223(1): 142-148.
59. Yin D, Vreeland F, Schaaf LJ, et al. Clinical pharmacodynamic effects of the growth hormone receptor antagonist pegvisomant: Implications for cancer therapy. Clin Cancer Res 2007; 13(3): 1000-1009.
60. Divisova J, Kuiatse I, Lazard Z, et al. The growth hormone receptor antagonist pegvisomant blocks both mammary gland development and MCF-7 breast cancer xenograft growth. Breast Cancer Res Treat 2006; 98(3): 315-327.
61. McCutcheon IE, Flyvbjerg A, Hill H, et al. Antitumor activity of the growth hormone receptor antagonist pegvisomant against human meningiomas in nude mice. J Neurosurg 2001; 94(3): 487-492.
62. Szereday Z, Schally AV, Varga JL, et al. Antagonists of growth hormone-releasing hormone inhibit the proliferation of experimental non-small cell lung carcinoma. Cancer Res 2003; 63(22): 7913-7919.
63. Goya M, Miyamoto S, Nagai K, et al. Growth inhibition of human prostate cancer cells in human adult bone implanted into nonobese diabetic/severe combined immunodeficient mice by a ligand-specific antibody to human insulin-like growth factors. Cancer Res 2004; 64(17): 6252-6258.
64. Sachdev D, Li SL, Hartell JS, et al. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I. Cancer Res 2003; 63(3): 627-635.
65. Wu JD, Odman A, Higgins LM, et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11(8): 3065-3074.
66. Burtrum D, Zhu Z, Lu D, et al. A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo. Cancer Res 2003; 63(24): 8912-8921.
67. Maloney EK, McLaughlin JL, Dagdigian NE, et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63(16): 5073-5083.
68. Goetsch L, Gonzalez A, Leger O, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer 2005; 113(2): 316-328.
69. Cohen BD, Baker DA, Soderstrom C, et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11(5): 2063-2073.
70. Lu D, Zhang H, Ludwig D, et al. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J Biol Chem 2004; 279(4): 2856-2865.
71. Hariharan K, Dong J, Demarest S, et al. BIIB022, a fully human nonglycosylated g4P antibody targeting IGF-1R for cancer therapy. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics; San Francisco (CA) 2007; Abs B210.
72. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004; 5(3): 221-230.
73. Carboni JM, Lee AV, Hadsell DL, et al. Tumor development by transgenic expression of a constitutively active insulin-like growth factor I receptor. Cancer Res 2005; 65(9): 3781-3787.
74. Garcia-Echeverria C, Pearson MA, Marti A, et al. In vivo Antitumor activity of NVP-AEW541-A novel, potent, and selective inhibitor of the IGF-IR kinase. Cancer Cell 2004; 5(3): 231-239.
75. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005; 10(15): 1041-1047.
76. Morgillo F, Kim WY, Kim ES, et al. Implication of the insulin-like growth factor-IR pathway in the resistance of non-small cell lung cancer cells to treatment with gefitinib. Clin Cancer Res 2007; 13(9): 2795-2803.
77. Karp DD, Paz-Ares L, Blakely J, et al. Efficacy of the anti-insulin like growth factor 1 receptor (IGF-1R) antibody CP-751871 in combination with paclitaxel and carboplatin as first-line treatment for advanced non-small cell lung cancer (NSCLC). ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; Vol. 25, No. 18S (June 20 Suppl): Abstr 7506.
78. Leary A, Dowsett M. Combination therapy with aromatase inhibitors: The next era of breast cancer treatment? Br J Cancer 2006; 95(6): 661-666.
79. Martin LA, Pancholi S, Chan CM, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005; 12(4): 1017-10136.
80. Helle SI, Holly JM, Tally M, et al. Influence of treatment with tamoxifen and change in tumor burden on the IGF-system in breast cancer patients. Int J Cancer 1996; 69(4): 335-339.
81. Wen B, Deutsch E, Marangoni E, et al. Tyrphostin AG 1024 modulates radiosensitivity in human breast cancer cells. Br J Cancer 2001; 85(12): 2017-2021.
82. Knowlden JM, Jones HE, Barrow D, et al. Insulin receptor substrate-1 involvement in epidermal growth factor receptor and insulin-like growth factor receptor signalling: Implication for Gefitinib ('Iressa') response and resistance. Breast Cancer Res Treat 2007; 111(1): 79-91.
83. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ. Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 2005; 65(23): 11118-11128.
84. Lu D, Zhang H, Koo H, et al. A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity. J Biol Chem 2005; 280(20): 19665-19672.
85. Chakraborty AK, Liang K, DiGiovanna MP. Co-targeting insulin-like growth factor I receptor and HER2: Dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer. Cancer Res 2008; 68(5): 1538-1545.
86. Nahta R, Yuan LX, Du Y, Esteva FJ. Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: Effects on insulin-like growth factor I signaling. Mol Cancer Ther 2007; 6(2): 667-674.
87. Harris LN, You F, Schnitt SJ, et al. Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res 2007; 13(4): 1198-1207.
88. Youngren JF, Gable K, Penaranda C, et al. Nordihydro-guaiaretic acid (NGDA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells. Breast Cancer Res Treat 2005; 94(1): 37-46.
89. Ji QS, Mulvihill MJ, Rosenfeld-Franklin M, et al. A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor dependent tumor growth in vivo. Mol Cancer Ther 2007; 6(8): 2158-2167.
90. Jones HE, Gee JM, Barrow D, et al. Inhibition of insulin receptor isoform-A signalling restores sensitivity to gefitinib in previously de novo resistant colon cancer cells. Br J Cancer 2006; 95(2): 172-180.
91. Ji Q-S, Mulvihill M, Franklin M, et al. Properties of small molecule IGF-IR kinase inhibitors in preclinical models. 98th AACR Annual Meeting April 14-18, 2007; LA California. AACR 2007: Abstr 2373.
92. Beltran PJ, Mitchell P, Moody G, et al. AMG-479, a fully human anti IGF-1 receptor antibody, inhibits PI3K/Akt signalling and exerts potent antitumour effects in combination with EGF-R inhibitors in pancreatic xenograft models. ASCO Gastrointestinal Cancers Symposium. 2007; Abstr 208.
93. Tonra JR, Corcoran E, Makhoul G, et al. Synergistic anti-tumor effects of anti-EGFR monoclonal antibody Erbitux(R) combined with antibodies targeting IGF1R or VEGFR-2. Proceedings of the AACR Annual Meeting. Proc Am Assoc Cancer Res 2005; 46: Abstr 5053.
94. Zhang HX, Lu D, Peyghambarian N, et al. Electro-optic properties of hybrid solgel doped with a nonlinear chromophore with large hyperpolarizability. Opt Lett 2005; 30(2): 117-119.
95. Yendluri V, Wright JR, Coppola D, et al. A small molecule inhibitor of insulin-like growth factor 1 receptor (PQIP) inhibits human pancreatic cancer cell proliferation in vitro and synergizes with erlotinib. ASCO Gastrointestinal Cancers Symposium 2008; Abstr 184.
96. Ueda S, Hatsuse K, Tsuda H, et al. Potential crosstalk between insulin-like growth factor receptor type 1 and epidermal growth factor receptor in progression and metastasis of pancreatic cancer. Mod Pathol 2006; 19(6): 788-796.
97. Gustafsson BI, Kidd M, Modlin IM. Neuroendocrine tumors of the diffuse neuroendocrine system. Curr Opin Oncol 2008; 20(1): 1-12.
98. Duran I, Salazar R, Casanovas O, et al. New drug development in digestive neuroendocrine tumors. Ann Oncol 2007; 18(8): 1307-1313.
99. Hopfner M, Baradari V, Huether A, Schofl C, Scherubl H. The insulin-like growth factor receptor 1 is a promising target for novel treatment approaches in neuroendocrine gastrointestinal tumours. Endocr Relat Cancer 2006; 13(1): 135-149.
100. Di Cosimo S, Seoane J, Guzman M, et al. Combination of the mammalian target of rapamycin (mTOR) inhibitor everolimus (E) with the Insulin like Growth Factor-1-Receptor (IGF-1-R) inhibitor NVP-AEW-541: A mechanistic based anti-tumor strategy. ASCO Annual Meeting Proceedings J Clin Oncol 2005; 23, No. 16S, Part I of II (June 1 Suppl): 3112.
101. Scotlandi K, Maini C, Manara MC, et al. Effectiveness of insulin-like growth factor I receptor antisense strategy against Ewing's sarcoma cells. Cancer Gene Ther 2002; 9(3): 296-307.
102. Scotlandi K, Benini S, Nanni P, et al. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res 1998; 58: 4127-4131.
103. Manara MC, Landuzzi L, Nanni P, et al. Preclinical in vivo study of new insulin-like growth factor-I receptor - specific inhibitor in Ewing's sarcoma. Clin Cancer Res 2007; 13(4): 1322-1330.
104. Scotlandi K, Manara MC, Nicoletti G, et al. Antitumor activity of the insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 in musculoskeletal tumors. Cancer Res 2005; 65(9): 3868-3876.
105. Martins AS, Mackintosh C, Martin DH, et al. Insulin-like growth factor I receptor pathway inhibition by ADW742, alone or in combination with imatinib, doxorubicin, or vincristine, is a novel therapeutic approach in Ewing tumor. Clin Cancer Res 2006; 12(11 Pt 1): 3532-3540.
106. Scotlandi K, Manara MC, Hattinger CM, et al. Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing's sarcoma. Eur J Cancer 2005; 41(9): 1349-1361.
107. Rodon J, Patnaik A, Stein M, et al. A phase I study of q3W R1507, a human monoclonal antibody IGF-1R antagonist in patients with advanced cancer. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; Vol. 25, No. 18S (June 20 Suppl): Abstr 3590.
108. Yuen JS, Macaulay VM. Targeting the type 1 insulin-like growth factor receptor as a treatment for cancer. Expert Opin Ther Targets 2008; 12(5): 589-603.
109. Letsch M, Schally AV, Busto R, Bajo AM, Varga JL. Growth hormone-releasing hormone (GHRH) antagonists inhibit the proliferation of androgen-dependent and -independent prostate cancers. Proc Natl Acad Sci USA 2003; 100(3): 1250-1255.
110. Higano CS, Yu YE, Whiting SH, et al. A phase I, first in man study of weekly IMC A-12, a fully human insulin like growth factor-I receptor IgG1 monoclonal antibody, in patients with advanced solid tumours. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25(18S)(June 20 Suppl): 3505.
111. Haluska P, Shaw HM, Batzel GN, et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13(19): 5834-5840.
112. de Bono JS, Adeji A, Attard G, et al. Circulating tumour cells expressing the insulin growth factor-1 receptor (IGF-1R): Method of detection, incidence and potential applications. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; Vol. 25, No. 18S (June 20 Suppl): 3507.
113. Fong P, Molife RL, Spicer J, et al. Phase I trial incorporating the pharmacodynamic (PD) study of circulating tumour cells (CTC) of CP-751,871 (C), a monoclonal antibody against the insulin-like growth factor 1 receptor (IGF-1R), in combination with docetaxel (D) in patients (p) with advanced cancer. Eur J Cancer Suppl 2006; 4(12): 61-62.
114. Ryan CJ, Youngren J, Zavodovskaya M, et al. Nordihydro-guareacetic acid (NDGA), a novel insulin-like growth factor receptor (IGF-1R) inhibitor in prostate cancer. ASCO Prostate Cancer Symposium 2006; Abstr 260.
115. Deutsch E, Maggiorella L, Wen B, et al. Tyrosine kinase inhibitor AG1024 exerts antileukaemic effects on STI571-resistant Bcr-Abl expressing cells and decreases AKT phosphorylation. Br J Cancer 2004; 91(9): 1735-1741.
116. Lakshmikuttyamma A, Pastural E, Takahashi N, et al. Bcr-Abl induces autocrine IGF-1 signaling. Oncogene 2008; 27(27): 3831-44.
117. Tazzari PL, Tabellini G, Bortul R, et al. The insulin-like growth factor-I receptor kinase inhibitor NVP-AEW541 induces apoptosis in acute myeloid leukemia cells exhibiting autocrine insulin-like growth factor-I secretion. Leukemia 2007; 21(5): 886-896.
118. Doepfner KT, Spertini O, Arcaro A. Autocrine insulin-like growth factor-I signaling promotes growth and survival of human acute myeloid leukemia cells via the phosphoinositide 3-kinase/Akt pathway. Leukemia 2007; 21(9): 1921-1930.
119. Mitsiades CS, Hayden PJ, Anderson KC, Richardson PG. From the bench to the bedside: Emerging new treatments in multiple myeloma. Best Pract Res Clin Haematol 2007; 20(4): 797-816.
120. Menu E, Jernberg-Wiklund H, De Raeve H, et al. Targeting the IGF-1R using picropodophyllin in the therapeutical 5T2MM mouse model of multiple myeloma: beneficial effects on tumor growth, angiogenesis, bone disease and survival. Int J Cancer 2007; 21(8): 1857-1861.
121. Stromberg T, Ekman S, Girnita L, et al. IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells. Blood 2006; 107(2): 669-678.
122. Pollak MN, Lacy MQ, Lipton A, et al. Pharmacodynamic properties of the anti-IGF-IR monoclonal antibody CP-751,871 in cancer patients. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; 25 18S (June 20 Suppl): Abstr 3587.
123. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, Pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor Type 1 receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26(19): 3196-3203.
124. Moreau P, Hulin C, Facon T, et al. Phase 1 study of AVE1642 anti IGF-1R monoclonal antibody in patients with advanced multiple myeloma. 49th Annual Meeting of the American Society of Hematology (ASH); Atlanta, Ga. Blood 2007.
125. Shi Y, Yan H, Frost P, Gera J, Lichtenstein A. Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/phosphatidylinositol 3-kinase cascade. Mol Cancer Ther 2005; 4(10): 1533-1540.
126. Yeh AH, Bohula EA, Macaulay VM. Human melanoma cells expressing V600E B-RAF are susceptible to IGF1R targeting by small interfering RNAs. Oncogene 2006; 25(50): 6574-6581.
127. Girnita A, All-Ericsson C, Economou MA, et al. The insulin-like growth factor-I receptor inhibitor picropodophyllin causes tumor regression and attenuates mechanisms involved in invasion of uveal melanoma cells. Clin Cancer Res 2006; 2(4): 1383-1391.
128. Gotlieb WH, Bruchim I, Gu J, et al. Insulin-like growth factor receptor I targeting in epithelial ovarian cancer. Gynecol Oncol 2006; 100(2): 389-396.
129. Pavelic K, Kolak T, Kapitanovic S, et al. Gastric cancer: The role of insulin-like growth factor 2 (IGF2) and its receptors (IGF 1R and M6-P/IGF 2R). J Pathol 2003; 201(3): 430-438.
130. Whitson BA, Jacobson BA, Frizelle S, et al. Effects of insulin-like growth factor-1 receptor inhibition in mesothelioma. Thoracic Surgery Directors Association Resident Research Award. Ann Thorac Surg 2006; 82(3): 996-1001; discussion -2.
131. Haluska P, Carboni J, Loegering DA, et al. In vitro and in vivo antitumor effects of the dual insulin-like growth factor-1/ insulin receptor inhibitor, BMS-554417. Cancer Res 2006; 66(1): 362-371.
132. Yakar S, Setser J, Zhao H, et al. Inhibition of growth hormone action improves insulin sensitivity in liver IGF-1-deficient mice. J Clin Invest 2004; 13(1): 96-105.
133. Kulkarni RN, Bruning JC, Winnay JN, et al. Tissue-specific knockout of the insulin receptor in pancreatic beta cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell 1999; 96(3): 329-339.
134. Withers DJ, Burks DJ, Towery HH, et al. Irs-2 coordinates Igf-1 receptor-mediated beta-cell development and peripheral insulin signalling. Nat Genet 1999; 23(1): 32-40.
135. Kulkarni RN, Winnay JN, Daniels M, et al. Altered function of insulin receptor substrate-1-deficient mouse islets and cultured beta-cell lines. J Clin Invest 1999; 104(12): 69-75.
136. Huang F, Hurburt W, Hafezi X, et al. Identification of sensistivity markers for BMS-536924, an inhibitor for insulin-like growth factor-1 receptor. ASCO Annual Meeting Proceedings Part I. J Clin Oncol 2007; Vol. 25, 18S (June 20 Suppl): Abstr 3506.
137. Girnita A, Girnita L, del Prete F, et al. Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor and malignant cell growth. Cancer Res 2004; 64(1): 236-242.
138. Vasilcanu R, Vasilcanu D, Rosengren L, et al. Picropodophyllin induces downregulation of the insulin-like growth factor 1 receptor: Potential mechanistic involvement of Mdm2 and beta-arrestin1. Oncogene 2008; 27(11): 1629-138.
139. Blum G, Gazit A, Levitzki A. Development of new insulin-like growth factor-1 receptor kinase inhibitors using catechol mimics. J Biol Chem 2003; 278(42): 40442-40454.
140. Bertrand FE, Steelman LS, Chappell WH, et al. Synergy between an IGF-1R antibody and Raf/MEK/ERK and PI3K/Akt/mTOR pathway inhibitors in suppressing IGF-1R-mediated growth in hematopoietic cells. Leukemia 2006; 20(7): 1254-1260.
141. Yi HK, Kim SY, Hwang PH, et al. Impact of PTEN on the expression of insulin-like growth factors (IGFs) and IGF-binding proteins in human gastric adenocarcinoma cells. Biochem Biophys Res Commun 2005; 330(3): 760-767.
142. Aftab D. Simultaneous inhibition of IGF1R and Src family kinases causes tumour growth inhibition and tumour regression in xenograft models. Eur J Cancer 2006; 4: 178.
143. Bassi DE, Mahloogi H, Lopez De Cicco R, Klein-Szanto A. Increased furin activity enhances the malignant phenotype of human head and neck cancer cells. Am J Pathol 2003; 162(2): 439-447.
144. Brown J, Delaine C, Zaccheo OJ, et al. Structure and functional analysis of the IGF-II/IGF2R interaction. EMBO J 2008; 27(1): 265-276.
145. Distefano, P., Bayley, C.A., Cannon, E.L.: WO2004022005A2 (2004).
146. Pienkos, P.T., Monticello, D.J.: WO2008005985 (2008).
147. Kung, A., Mitsiades, C.S., Mitsiades, N.: WO2005082415 (2005).
148. Ludwig, D., Plymate, S.R.: WO2007092453 (2007).
149. Shang, Y., Stephan, J.F., Wu, Y., Zha, J.: WO2008079849 (2008).